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Abstract
Osteonecrosis of the jaw induced by administration of bisphosphonates (BPs), BP-related
osteonecrosis (BRONJ), typically develops after tooth extraction and is medically challeng-
ing. As BPs inhibit oral mucosal cell growth, we hypothesized that suppression of the wound
healing-inhibiting effects could prevent BRONJ onset after tooth extraction. Since basic fibro-
blast growth factor (bFGF) promotes wound healing, but has a short half-life, we examined
whether the initiation of BRONJ could be prevented by applying a bFGF-containing gelatin
hydrogel over the extraction sockets of BRONJ model rats. Forty-three rats, received two
intravenous injections of zoledronic acid 60 μg/kg, once per week for a period of 2 weeks,
underwent extraction of a unilateral lower first molar. The rats here were randomly assigned
to the bFGF group (n = 15 rats, gelatin hydrogel sheets with incorporated bFGF applied over
the sockets); the phosphate-buffered saline (PBS) group (n = 14 rats, gelatin hydrogel sheets
without bFGF applied over the sockets); or the control group (n = 14 rats, nothing applied
over the sockets). One rat in the bFGF group was sacrificed immediately after tooth extrac-
tion. Twenty-one rats were sacrificed at 3 weeks, and the remaining 21 rats were sacrificed
at 8 weeks after tooth extractions. The harvested mandibles were analyzed using micro-com-
puted tomography and sections were evaluated qualitatively for mucosal disruption and
osteonecrosis. The incidence of osteonecrosis at 8 weeks after tooth extraction was 0% in
the bFGF group, 100% in the PBS group, and 85.7% in the control group. The frequency of
complete coverage of the extraction socket by mucosal tissue was significantly greater in the
bFGF group than in the other groups. These results suggest that application of bFGF in the
extraction socket promoted socket healing, which prevented BRONJ development. The
growth-stimulating effects of bFGF may have offset the inhibition of wound healing by BP.
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Introduction
Bisphosphonates (BPs) that inhibit bone resorption are frequently used to treat osteoporosis,
skeletal-related events, multiple myeloma, Paget’s bone disease, and other conditions that
result in bone fragility [1–3]. However, osteonecrosis of the jaw induced by administration of
BPs, BP-related osteonecrosis (BRONJ), has become a serious problem.
The severity of BRONJ is classified into four stages on the basis of clinical and radiographic
findings, and stage-specific treatment strategies have been proposed (Table 1). Nevertheless,
once established, BRONJ is often refractory to treatment and tends to be progressive. In a
cohort study characterizing BRONJ among patients receiving intravenous BPs over a median
follow-up period of 1.5 years, 25%, 48%, and 27% of patients receiving stage-specific treatment
improved, stayed within the same stage, and worsened, respectively [4]. Progression of BRONJ
in terms of severity causes pathologic fractures, oral antral/oral nasal communication, extra-
oral fistulas, and so on, resulting not only in a marked decrease in quality of life [5], but also
sometimes in a fatal outcome due to sepsis [6]. At present, no standard of treatment for
BRONJ has been established; thus, it is important to prevent the onset of BRONJ.
The pathogenesis of BP-induced BRONJ is thought to involve inhibition of osteoclastic
bone resorption and remodeling, inhibition of angiogenesis, soft tissue toxicity, immune dys-
function, etc. [3]. It has been reported that 63.7% of BRONJ cases are associated with tooth
extraction [7]; hence, the influence of BPs on bone remodeling has been actively studied. How-
ever, the effects have not yet been clarified, and no prophylaxis has been established.
In this study, we focused on the effects of BPs on soft tissue toxicity. Recent basic research
has revealed that BPs inhibit the growth of oral mucosal cells [8]. Therefore, we hypothesized
that suppression of the inhibitory effects of BPs on wound healing could prevent the initiation
of BRONJ after tooth extraction. We speculated that the application of basic fibroblast growth
factor (bFGF), which promotes wound healing [9], over the tooth extraction sockets, could
prevent the initiation of BRONJ after tooth extraction. However, bFGF has an extremely short
half-life in vivo (more than 80% of the bFGF injected subcutaneously was eliminated from the
injected site within 24 hours [10]). We therefore focused on gelatin hydrogel as a representa-
tive drug delivery system [11]. This carrier allows controlled release of incorporated growth
factors over a long period of time [12–14]. Hence, in this study, we examined whether the
onset of BRONJ could be prevented by applying gelatin hydrogel containing bFGF over the
extraction sockets of rats administered BPs.
Table 1. Staging and treatment strategies for BRONJ.
Stage Description Treatment strategies
0 Non-specific clinical findings, radiographic findings
and symptoms. No clinical evidence of necrotic bone.
Systemic management. Use of analgesics and
antibiotics.
1 Asymptomatic, but exposed and necrotic bone or
fistulas are present. No evidence of infection.
Use of chlorhexidine mouthrinse, close monitoring
of patient on quarterly basis. Provide patient
education.
2 Exposed necrotic bone or fistulas that probes to bone
in area of infection. Clinical signs of infection, such as
pain, erythema with or without purulent discharge.
Symptomatic treatment with antibiotics, oral
bacterial mouthrinse, pain control, debridement of
infected area.
3 Exposed necrotic bone or fistulas present that probes
to bone and extends beyond region of alveolar bone,
such as to inferior border of mandible, ramus of
mandible, and zygoma in maxilla. Fracture of jaw or
osteolysis present in jaws.
All of the above treatment, plus more aggressive
surgical intervention, such as debridement and
resection of jaw.
Taken from Ruggiero et al. [3]
https://doi.org/10.1371/journal.pone.0211928.t001
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Materials and methods
Preparation of gelatin hydrogel sheets
Gelatin with an isoelectric point of 5.0 was supplied by Nitta Gelatin (Osaka, Japan), and
human recombinant bFGF with an isoelectric point of 9.6 was supplied by Kaken Pharmaceu-
tical (Tokyo, Japan). Gelatin hydrogel sheets were made as previously described [15] through
chemical crosslinking of aqueous gelatin solution with 25% glutaraldehyde (Nacalai Tesque,
Inc., Kyoto, Japan). Briefly, polytetrafluoroethylene molds were filled with 5% aqueous gelatin
solution containing glutaraldehyde. Crosslinking was allowed to proceed at 4˚C for 12 hours,
and the resultant hydrogel was immersed in 100 mM glycine aqueous solution at 37˚C for 1
hour to block the residual aldehyde groups of the glutaraldehyde. Thereafter, the gelatin
hydrogel was freeze-dried and gelatin hydrogel sheets with 95% water content were produced.
To prepare the gelatin hydrogel sheets incorporating bFGF, 100 μg of bFGF was diluted
with 200 μl of PBS (Gibco, Life Technologies, Roskilde, Denmark). Next, bFGF was incorpo-
rated into the gelatin hydrogel sheet by dropping 200 μl of bFGF solution onto a freeze-dried
gelatin hydrogel sheet (20 mg, 11 mm × 13 mm, 1.0-mm thick), which was then left at 37˚C
for 1 hour. Gelatin hydrogel sheets without bFGF were prepared by dropping 200 μl of PBS
onto a freeze-dried gelatin hydrogel sheet (20 mg, 11×13 mm, 1.0 mm thick), which were then
left at 37˚C for 1 hour.
Creation of a rat BRONJ model
This animal study was approved by the animal care and use committee of Nara Medical Uni-
versity (Permit Number: 11756). Forty-three female Sprague-Dawley (SD) rats (Japan SLC,
Shizuoka, Japan), aged 10 weeks, were used in this study. The rats were kept in an environment
with a controlled temperature and 12-hour light–dark cycles, with food and water supplied ad
libitum. Surgery was performed under general anesthesia and all efforts were made to mini-
mize suffering.
We conducted this study using a rat BRONJ model, similar to the model used in a previous
study by Borke et al. [16]. All rats received two intravenous injections of zoledronic acid (ZA)
60 μg/kg based on the human dosage of 4 mg/65.8 Kg, once per week for a period of 2 weeks.
The second dose was administered on the date of the molar extraction, 1 week after the first
dose. The intravenous ZA injections were administered into the tail vein, after application of a
rubber band tourniquet placed at the base of the tail to reveal the vein. After induction of anes-
thesia with a single intraperitoneal injection of pentobarbital sodium 50 mg/kg, extraction of
the unilateral lower first molar was performed in each rat (Fig 1). The previous study [16] and
our own preliminary experiments (S1 Fig) showed that none of the non-ZA-treated rats exhib-
ited osteonecrosis.
A gingival sulcus incision was made around the lower first molar using a #11 surgical blade.
A mucoperiosteal flap was raised using a periosteal elevator. The molars were removed using a
sharpened dental explorer. A 2-mm-diameter twist drill was used to expand the extraction
sockets to a standardized depth of 2 mm. Each extraction socket was expanded with a drill to
create a standardized bone defect with a size of 2 × 2 × 3 mm. The rats were randomly assigned
to one of three groups, as follows: the bFGF group (n = 15 rats), where gelatin hydrogel sheets
with bFGF incorporated were applied over the alveolar defects; the phosphate-buffered saline
(PBS) group (n = 14 rats), where gelatin hydrogel sheets without bFGF were applied over the
defects; and the control group (n = 14 rats), where nothing was applied over the defects. The
prepared gelatin hydrogel sheet with or without bFGF (for the bFGF and PBS groups), or
nothing (for the control group) was placed in the defect. Finally, the bone defect was sutured
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by placing a horizontal mattress suture using 5/0 polypropylene. One rat in the bFGF group
was sacrificed immediately after tooth extraction for comparison with time. Twenty-one rats
were sacrificed at 3 weeks after tooth extractions, and the remaining 21 rats were sacrificed
at 8 weeks after tooth extractions. Rats were sacrificed by exsanguination under general
anesthesia.
Fig 1. Application of a gelatin hydrogel sheet incorporating bFGF. (a) The lower first molar before extraction. (b)
After tooth extraction, the extraction socket was expanded with a twist drill to create a bone defect (open arrow). (c)
The alveolar defect after applying a gelatin hydrogel sheet (open arrowhead). (d) The bone defect was sutured
primarily (filled arrow).
https://doi.org/10.1371/journal.pone.0211928.g001
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Micro-computed tomography (CT) analysis
The harvested mandibles were analyzed using a micro-CT system (Toscaner-32300 μ-FPD;
Toshiba IT and Control Systems, Tokyo, Japan). Each mandible was scanned at intervals of
38 μm at 100 kV and 200 μA. Three-dimensional images were constructed using VG Studio
software (Volume Graphics, Heidelberg, Germany).
The finding in each alveolar defect was assessed on a coronal section 1.0-mm mesial from
the mesial surface of the lower second molar. Additionally, to examine the newly formed bone
in the defect 3 or 8 weeks after tooth extractions, we measured the calcification areas (which
were high-density areas, and defined as having a density equal to or greater than 150 CT units
[17]), within the region of interest (ROI) in the socket (Fig 2a). By auto-interpolation between
layers, ROI became the volume of interest (VOI) in the area between the coronal section 1.0-
and 1.5-mm mesial from the mesial surface of the lower second molar (Fig 2b). VOI was deter-
mined to be 0.125 mm3, and the volume of the newly formed bone was calculated within the
VOI. We used ImageJ software (v. 1.49; NIH, Bethesda, MD, USA) for the analysis.
Histological analysis
After micro-CT analysis, all mandibles were fixed in 10% formaldehyde neutral buffer solu-
tion, decalcified with 0.5 mol/l EDTA, and embedded in paraffin. Thin sections, 5 μm in thick-
ness, were cut at 1.0-mm mesial from the mesial surface of the lower second molar in the
buccolingual direction and stained with hematoxylin and eosin (H&E) for a light microscopic
examination. These sections were evaluated qualitatively for the presence or absence of muco-
sal disruption and osteonecrosis. Osteonecrosis was defined as exposed bone persistent at 8
weeks postoperatively. Moreover, the total number of empty osteocyte lacunae per extraction
socket were determined 3 and 8 weeks after tooth extraction, and compared among the study
groups. Investigators, blinded to the results of the micro-CT analyses and to the identification
of the rat groups, independently performed the histological analysis.
Statistical analysis
To assess the significance of differences in the volumes of newly formed bone, as determined
by micro-CT analysis, and the total number of empty osteocyte lacunae per extraction socket,
as determined by histological analysis, statistical analysis was performed using the Mann-
Whitney U test. The incidence of alveolar defects with exposed bone based on macroscopic
findings and the presence or absence of mucosal disruption and osteonecrosis determined by
histological analysis were evaluated using Steel’s test. Differences with P values of less than
0.05 were considered significant for both tests.
Results
Changes in body weight
The mean body weight of the rats was 215.0 g (SE 2.1 g) at the beginning of ZA administration
and 227.6 g (SE 2.4 g) after tooth extraction. In addition, the mean body weights of rats at the
time of sacrifice 3 and 8 weeks after tooth extraction were 243.3 g (SE 3.5 g) and 278.1 g (SE
6.3 g), respectively. Thus, regardless of the treatment after tooth extraction, the body weight
increased in all rats.
Macroscopic findings
Three weeks after tooth extraction, the extraction socket in the bFGF group (Fig 3a) was cov-
ered with normal mucosa, similar to the surrounding areas, demonstrating no signs of
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Fig 2. Setting of the region of interest (ROI) and the volume of interest (VOI) in the alveolar defect. (a) The ROI was set at 1.0-mm mesial from the
mesial surface of the lower second molar on the CT coronal section. The tangent line passing through the highest point of the incisor, parallel to the
occlusal plane, was set as the x-axis, and the perpendicular line passing through that point was set as the y-axis. The highest point of the incisor was set
as the origin, and a square region of 0.5 mm × 0.5 mm with vertices at (x, y) = (1 mm, 1 mm), (1 mm, 1.5 mm), (1.5 mm, 1 mm), (1.5 mm, 1 mm), and
(1.5 mm, 1.5 mm) was defined as the ROI. (b) By auto-interpolation between layers, ROI became the volume of interest (VOI) in the area between the
coronal sections 1.0- and 1.5-mm mesial from the mesial surface of the lower second molar. The volumes of the newly formed bone in this VOI were
determined 3 and 8 weeks after tooth extraction, and compared among the study groups. (2D, two-dimensional view; 3D, three-dimensional view; 2 M,
lower second molar; 3 M, lower third molar).
https://doi.org/10.1371/journal.pone.0211928.g002
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Fig 3. Typical macroscopic findings. (a) Extraction socket in the bFGF group at 3 weeks after tooth extraction. (b) Extraction socket in the
PBS group at 3 weeks after tooth extraction. (c) Extraction socket in the control group at 3 weeks after tooth extraction. (d) Extraction socket
in the bFGF group at 8 weeks after tooth extraction. (e) Extraction socket in the PBS group at 8 weeks after tooth extraction. (f) Extraction
socket in the control group at 8 weeks after tooth extraction. The extraction sockets in the bFGF group at 3 and 8 weeks (a, d) after the tooth
extraction socket was covered with normal mucosa, similar to the surrounding areas, and demonstrating no signs of inflammation. The
concavities of the sockets were still present at 3 weeks after tooth extraction (a), but there was no residual socket concavity at 8 weeks after
tooth extraction (d). The extraction sockets in the PBS group (b) and the control group (c) at 3 weeks after tooth extraction showed exposed
bone of normal color. The extraction sockets in the PBS group (e) and the control group (f) at 8 weeks after tooth extraction showed
discolored, brownish exposed bone.
https://doi.org/10.1371/journal.pone.0211928.g003
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inflammation, such as redness; however, the concavities of the sockets were still present. The
extraction sockets in the PBS group (Fig 3b) and the control group (Fig 3c) showed exposed
bone of normal color and without pus discharge.
Eight weeks after tooth extraction, the extraction socket in the bFGF group (Fig 3d) showed
no inflammatory changes, and was covered with normal mucosa. Additionally, there were no
residual socket concavities. The extraction sockets in the PBS group (Fig 3e) and the control
group (Fig 3f) showed discolored, brownish exposed bone, sometimes with accompanying pus
discharge.
The incidence of osteonecrosis based on the macroscopic finding of exposed necrotic bone
at 3 and 8 weeks after tooth extraction was evaluated (Table 2). The incidence of osteonecrosis
in the bFGF group, the PBS group, and the control group at 3 weeks after tooth extraction was
14.3% (1/7), 71.4% (5/7), and 85.7% (6/7), respectively. The incidence of osteonecrosis in the
control group was significantly higher than in the bFGF group. The incidence of osteonecrosis
in the bFGF group, the PBS group, and the control group at 8 weeks after tooth extraction
were 0% (0/7), 57.1% (4/7), and 57.1% (4/7), respectively. The incidence of osteonecrosis in
the PBS group and the control group were significantly higher than in the bFGF group.
Micro-CT findings
Compared to the micro-CT images obtained immediately after tooth extraction (Fig 4a), the
images obtained at 3 weeks after extraction revealed no marked difference in the morphology
of alveolar defects between each group (Fig 4b–4d). Micro-CT images obtained 8 weeks after
tooth extraction showed bone formation in the extraction sockets in the bFGF group (Fig 4e).
On the other hand, small bone fragments suggestive of sequestra were found without evident
bone formation in the PBS group (Fig 4f) and the control group (Fig 4g).
The volume of the newly formed bone in the alveolar defects was quantified in each group
at 3 and 8 weeks after tooth extraction (Fig 5). There was hardly any bone formation (0.0067–
0.010 mm3) in any of the groups at 3 weeks after tooth extraction, with no significant differ-
ences among the groups. On the other hand, the volumes of the newly formed bone at 8 weeks
after tooth extraction were 0.0686 mm3 (SE 0.0244 mm3) in the bFGF group, 0.0010 mm3 (SE
0.0008 mm3) in the PBS group, and 0.0010 mm3 (SE 0.0007 mm3) in the control group, show-
ing a significantly greater amount of bone formation in the bFGF group than in the other
groups (p = 0.015, against the PBS group; p = 0.015, against the control group). When the vol-
umes of the newly formed bone at 3 and 8 weeks after tooth extraction in the bFGF group
were compared, bone formation was found to be significantly greater at 8 weeks (p = 0.015).
Histological findings
Gelatin hydrogel was present in the extraction sockets of treated rats immediately after tooth
extraction (Fig 6a), but did not remain there in any group at 3 and 8 weeks after tooth extrac-
tion (Fig 6b–6g). The presence or absence of mucosal disruption in the alveolar defects were
evaluated at 3 weeks after tooth extraction (Table 3). In the bFGF group (Fig 6b), mucosal
Table 2. The incidence of extraction sockets with exposed bone based on macroscopic findings.
bFGF PBS Control
3 weeks after tooth extraction 1/7 (14.3%) 5/7 (71.4%) 6/7� (85.7%)
8 weeks after tooth extraction 0/7 (0%) 4/7� (57.1%) 4/7� (57.1%)
� P<0.05 vs. bFGF
https://doi.org/10.1371/journal.pone.0211928.t002
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Fig 4. Typical micro-CT images. (a) Alveolar defect in the bFGF group immediately after tooth extraction. (b) Alveolar defect in the bFGF group
at 3 weeks after tooth extraction. (c) Alveolar defect in the PBS group at 3 weeks after tooth extraction. (d) Alveolar defect in the control group at
3 weeks after tooth extraction. (e) Alveolar defect in the bFGF group at 8 weeks after tooth extraction. (f) Alveolar defect in the PBS group at 8
weeks after tooth extraction. (g) Alveolar defect in the control group at 8 weeks after tooth extraction. There was no bone formation in the
alveolar defects in any group at 3 weeks after tooth extraction (b–d). Whereas bone formation was found in the bFGF group (e) at 8 weeks after
tooth extraction, no such bone formation was found in the PBS group (f) and the control group (g), but small bone fragments suggestive of bone
sequestra were present at this time point.
https://doi.org/10.1371/journal.pone.0211928.g004
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disruption was found in 14.3% (1/7) of alveolar defect samples. In contrast, the corresponding
percentages for mucosal disruption in the PBS group (Fig 6c) and the control group (Fig 6d)
were 85.7% (6/7) samples and 100% (7/7) samples, respectively, which were significantly
higher than in the bFGF group.
The alveolar defects examined at 8 weeks after tooth extraction showed no osteonecrosis in
the bFGF group (Fig 6e). On the other hand, in the PBS group (Fig 6f) and in the control
group (Fig 6g), osteonecrosis was present in 100% (7/7) and 85.7% (6/7) of samples, respec-
tively; this was significantly greater than in the bFGF group, similar to the findings at 3 weeks
after tooth extraction.
The total number of empty osteocyte lacunae per extraction socket was quantified in each
group at 3 and 8 weeks after tooth extraction (Fig 7). The total number of empty osteocyte
Fig 5. The volume of newly formed bone in the extraction socket. The volume of newly formed bone in the bFGF group at 8 weeks after tooth
extraction was significantly greater than the corresponding volumes in the PBS group and the control group at 8 weeks after tooth extraction, as well as
in the bFGF group at 3 weeks after tooth extraction. Each error bar denotes 1 standard error.
https://doi.org/10.1371/journal.pone.0211928.g005
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Fig 6. Typical histological findings. (a) Alveolar defect in the bFGF group immediately after tooth extraction. The gelatin
hydrogel applied in the defect is indicated as a dotted line. (b) Alveolar defect in the bFGF group at 3 weeks after tooth
extraction. (c) Alveolar defect in the PBS group at 3 weeks after tooth extraction. (d) Alveolar defect in the control group at
3 weeks after tooth extraction. (e) Alveolar defect in the bFGF group at 8 weeks after tooth extraction. (f) Alveolar defect in
the PBS group at 8 weeks after tooth extraction. (g) Alveolar defect in the control group at 8 weeks after tooth extraction.
There was no mucosal disruption in the bFGF group at 3 and 8 weeks after tooth extraction (b, e). The defect was filled with
granulation tissue (�) and new bone (NB) at 3 and 8 weeks after tooth extraction, respectively. Numerous osteocytes were
presented in their lacunae in the bFGF group at 3 and 8 weeks after tooth extraction (inset b, e). In the group, mild
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infiltration of inflammatory cells, consisting mainly of neutrophils, was observed with multinucleated giant cells at 3 weeks
after tooth extraction, but the infiltration was scarce at 8 weeks after tooth extraction. Mucosal disruption (black line) was
present in the PBS group (c, f) and in the control group (d, g) at 3 and 8 weeks after tooth extraction, and there was no bone
formation. Numerous empty osteocyte lacunae were observed in the PBS group and in the control group at 3 and 8 weeks
after tooth extraction (inset c, d, f, g). Additionally, severe inflammatory cell infiltration, mainly comprising neutrophils,
was observed in the PBS group and the control group at 3 and 8 weeks after tooth extraction (hematoxylin and eosin stain;
original magnification ×4, inset magnification ×40).
https://doi.org/10.1371/journal.pone.0211928.g006
Table 3. Histologic findings of each group.
bFGF PBS Control
Mucosal disruption (at 3 weeks after tooth extraction) 1/7 (14.3%) 6/7� (85.7%) 7/7� (100%)
Osteonecrosis (at 8 weeks after tooth extraction) 0/7 (0%) 7/7� (100%) 6/7� (85.7%)
�P < 0.05 vs. bFGF
https://doi.org/10.1371/journal.pone.0211928.t003
Fig 7. The total number of empty osteocyte lacunae per extraction socket. The total number of empty osteocyte lacunae per extraction socket in the
bFGF group at 3 and 8 weeks after tooth extraction was significantly lower than the total empty osteocyte lacunae in the PBS group and the control
group at 3 and 8 weeks after tooth extraction. Each error bar denotes 1 standard error.
https://doi.org/10.1371/journal.pone.0211928.g007
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lacunae at 3 weeks after tooth extraction were 957 (37.1% of the total cell count, SE 221) in the
bFGF group, 2902 (87.2% of the total cell count, SE 364) in the PBS group, and 3130 (87.7% of
the total cell count, SE 338) in the control group, showing a significantly lower number in the
bFGF group than in the other groups (p = 0.0027, against the PBS group; p = 0.0017, against
the control group). In addition, the total number of empty osteocyte lacunae at 8 weeks after
tooth extraction were 382 (20.1% of the total cell count, SE 142) in the bFGF group, 2919
(87.7% of the total cell count, SE 385) in the PBS group, and 2602 (73.0% of the total cell count,
SE 520) in the control group, showing a significantly lower number in the bFGF group than in
the other groups (p = 0.0017, against the PBS group; p = 0.0017, against the control group).
Discussion
As measures for preventing BRONJ triggered by tooth extraction, infection prophylaxis,
including complete removal of potential sources of infection, improvement of oral hygiene,
antimicrobial medication before tooth extraction, and closing the extraction socket, have been
recommended [5, 18, 19]. However, it is difficult to prevent the occurrence of BRONJ by infec-
tion prophylaxis alone, and therefore the development of a new prophylactic measure is
awaited. This study was performed to verify whether application of bFGF to the extraction
socket would prevent the occurrence of BRONJ after tooth extraction. We performed tooth
extraction in rats that were administered BP, and investigated the incidence of osteonecrosis
after application of bFGF-containing gelatin hydrogel into the alveolar defects. The incidence
of osteonecrosis at 8 weeks after tooth extraction was 0% in the bFGF group, 100% in the PBS
group, and 85.7% in the control group, showing a markedly lower rate in the bFGF group than
in the other groups. These results suggest that application of bFGF in the extraction socket can
prevent the occurrence of BRONJ after tooth extraction. This is an entirely new preventive
method that has not been reported previously.
In addition, to examine the effects of bFGF on the oral mucosa, mucosal healing in the
extraction socket at 3 weeks after tooth extraction was investigated. The frequency of complete
coverage of the extraction socket by mucosal tissue was significantly greater in the bFGF group
than in the other groups. It can be inferred from these findings that wound healing in the
extraction socket was facilitated by bFGF, and this facilitated the prevention of BRONJ. It can
be presumed that inhibition of socket healing due to BP was offset by the growth-stimulating
effect of bFGF. These findings suggest that BP-induced inhibition of wound healing may have
a significant role in the initiation of BRONJ, as was also observed in a previous study [8].
Although bFGF is clinically used for the treatment of intractable skin ulcers, such as
decubitus ulcers, burn ulcers, and diabetic ulcers [9, 20, 21], it is used mainly by repeated
administration [22] because bFGF has a short half-life [10]. However, in order to apply it to
the extraction socket, a method for achieving a therapeutic effect with a single dose was neces-
sary. To this end, we used a slow-release bFGF using a gelatin hydrogel drug-delivery system.
Because bFGF forms an ion complex with gelatin hydrogel, it is released slowly as the gelatin
hydrogel degraded enzymatically [12–15, 23]. The time period of gelatin hydrogel degradation
in vivo varies, depending on its water content [13–15, 23]. In this study, the water content of
the gelatin hydrogel was set at 95%, referring to a previous report [24]. It is demonstrated that
gelatin hydrogel with a water content of 95% allowed release of about 20% of incorporated
bFGF within the first few hours, and that the remaining bFGF is released slowly as the gelatin
hydrogel is degraded over a time period of 2 weeks [14, 24]. The combination ratio of bFGF
and gelatin hydrogel was set at 100 μg bFGF/20 mg gelatin hydrogel, based on a previous
report [24]. In future, the optimal time profile of bFGF release and the optimal combination
ratio to the gelatin hydrogel should be investigated further.
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Although this study suggested that bFGF-containing gelatin hydrogel could be an excellent
agent to prevent the occurrence of BRONJ after tooth extraction, it is necessary to recognize
the limitations of this study. This study did not include a continuous investigation of the same
individuals, and therefore, our view that the development of BRONJ was prevented by early
mucosal healing in the extraction socket remains speculative. It also remains unclear whether
and how factors other than mucosal healing in the extraction socket, facilitated by bFGF, con-
tribute to the inhibition of BRONJ development. It is known that bFGF promotes not only
mucosal healing, but also proliferation of osteoblasts, differentiation and migration of osteo-
clasts, immune function, and angiogenesis [25–31]. These actions are considered to offset the
influence of BPs on the jawbone. For instance, even though inhibition of bone growth in the
extraction socket by BPs was reported previously [32], growth of bone was observed in this
study. It is speculated that not only indirect facilitation of bone growth by early mucosal heal-
ing in the extraction socket but also direct actions of bFGF such as improvement of bone
remodeling and acceleration of angiogenesis are involved. Elucidation of the mechanism by
which bFGF inhibits the occurrence of BRONJ may clarify the pathology of BRONJ, which
remains unclear at present.
Currently, clinical research of bFGF-containing gelatin hydrogel for the treatment of avas-
cular necrosis of the femoral head or critical limb ischemia is underway, and a phase II study,
which has yielded favorable results, is being completed [33, 34]. We also plan to investigate the
usefulness of bFGF-containing gelatin hydrogel in a phase II clinical study in patients who
have a history of treatment with BPs.
Supporting information
S1 Fig. Macroscopic, micro-CT, and histological findings of non-zoledronic acid treated
rats. Six non-zoledronic acid (ZA)-treated rats underwent unilateral extraction of a lower first
molar, in the same manner as ZA-treated rats. Four rats were sacrificed at 3 weeks; the remain-
ing two rats were sacrificed at 8 weeks after tooth extraction. (a) Three weeks after tooth
extraction, macroscopic examination showed all non-ZA samples were covered with normal
mucosa. (b) All micro-CT images obtained at 3 weeks after tooth extraction showed new bone
formation in the extraction sockets, but not at the alveolar crests. (c) Three weeks after tooth
extraction, histological examination showed no mucosal disruption in non-ZA samples.
(d) Eight weeks after tooth extraction, macroscopic examination showed all non-ZA samples
were covered with normal mucosa. (e) All micro-CT images obtained at 8 weeks after tooth
extraction showed extraction sockets that were filled with new bone. (f) Eight weeks after
tooth extraction, histological examination showed no osteonecrosis in non-ZA samples.
(TIF)
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